Biomedcode scientists have coauthored a paper published in Scientific Reports  that provides for the first time a possible mechanistic explanation to the growth retardation commonly observed in children with chronic inflammatory diseases treated with glucocorticoids. The Tg197 human TNF transgenic mice were used as a tool to show that TNF overexpression and dexamethasone treatment impair bone growth separately and in an additive manner.

Published in Scientific Reports 2022 Oct 28;12(1):18189. doi: 10.1038/s41598-022-22734-8

Read More

Biomedcode is in search  of an individual or company with proven experience in Intellectual Property  exploitation to take over the management of the IP of its drug discovery projects. The ideal candidate will lead initiatives to generate and engage with business partners to exploit the company’s IP portfolio. Critical thinking and a demonstrated ability to execute a particular IP exploitation strategy, identify partnerships and financing opportunities in the life sciences industry  as well as develop and manage IP commercialization strategies are required.

Read More

Biomedcode is pleased to announce that, the T2EDK program -development of a bronchoscopic biopsies-on-chip (BioOnChip) platform for immunotherapy drug screening in non-small cell lung cancer- initiated in collaboration with the BSRC Al. Fleming researcher M. Tsoumakidou, the Department of Computer Science and Biomedical Informatics of the University of Thessaly and the Pulmonary Clinic of the University of Ioannina has been financed by the European Union – Next Generation EU and the National Recovery and Resilience Plan Greece 2.0 funds. BioOnChip aims to explore the applicability of an innovative 3D microfluidic microculture, i.e. tumor-on-chip, in predicting real-time responses to PD1-blockade in NSCLC patients, that, if efficient, might have important socioeconomic impact.